A Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3113593 in Healthy Subjects and Patients With Chronic Kidney Disease Treated With Hemodialysis

Fecha de inicio: 1 de junio de 2014

Inclusion Criteria: * Healthy Participants: * Healthy males or females * Participants have a body mass index (BMI) of 18.5 to 29.9 kilogram per meter square (kg/m\^2), inclusive at screening * Participants Treated with Hemodialysis: * Participants are males or females who have end-stage renal disease (ESRD) and have been receiving adequate maintenance hemodialysis (3 times weekly) for at least 12 weeks prior to screening * Participants have a hemoglobin value greater than or equal to (≥)9.0 grams per deciliter (g/dL) and less than or equal to (≤)12.5 g/dL at screening * Participants have a body mass index (BMI) of 18.5 to 45.0 kg/m\^2, inclusive, at screening * Both Populations: * Male participants agree to use a reliable method of birth control and avoid donating sperm during the study and for 3 months following the dose of the investigational product * Female participants must not be of child-bearing potential Exclusion Criteria: * Healthy Participants: * Participants that have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data * Participants that have used or intend to use over-the-counter or prescription medication, including herbal medications within 14 days prior to dosing * Participants Treated with Hemodialysis: * Participants that have a history of myocardial infarction, acute coronary syndrome, stroke or transient ischemic attacks within the prior 6 months * Participants that have heart failure that results in dyspnea at rest or during minimal exercise * Participants that have poorly controlled hypertension * Participants that have a history of significant thrombotic disease, pulmonary hypertension, significant hematological disease or current liver disease, known hepatic or biliary abnormalities * Participants that had a blood transfusion within the prior 12 weeks or an anticipated need for blood transfusion during the study * Participants that have evidence of active peptic, duodenal, or esophageal ulcer disease or gastrointestinal bleeding within the prior 12 weeks * Both Populations: * Participants that have known allergies to related compounds or any components of the study drug or its formulation, clinically significant multiple or severe drug allergies, or intolerance to topical corticosteroids, or severe post treatment hypersensitivity reactions or history of significant atopy * Participants that have participated, within the last 30 days (or 5 half-lives if long half life) in a clinical trial involving an investigational product * Participants that have known or ongoing psychiatric disorders